Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H26N4O5S.ClH |
| Molecular Weight | 470.97 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)CC1=CC=C(CSCCNC(NCC2=CC=C3OCOC3=C2)=C[N+]([O-])=O)O1
InChI
InChIKey=YGFCDHGCXUXBRI-BGDWDFROSA-N
InChI=1S/C20H26N4O5S.ClH/c1-23(2)11-16-4-5-17(29-16)13-30-8-7-21-20(12-24(25)26)22-10-15-3-6-18-19(9-15)28-14-27-18;/h3-6,9,12,21-22H,7-8,10-11,13-14H2,1-2H3;1H/b20-12+;
Niperotidine is an H2 antagonist structurally related to ranitidine. H2 antagonists inhibit gastric acid secretion by selectively blocking histamine receptor type 2. Niperotidine was proposed for the treatment of peptic ulcer. Bedtime dose of niperotidine inhibits nocturnal gastric acid secretion in healthy subjects. The duration of niperotidine action was 5 to 7 hours. Twenty-five cases of acute hepatitis (including one death from fulminant hepatitis) associated with niperotidine use were reported in Italy between March and August 1995 and drug was withdrawn from the market. The methylenedioxy group of niperotidine is known to undergo metabolism to catechol and quinone metabolites.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB03436MIG
Created by
admin on Mon Mar 31 21:35:56 GMT 2025 , Edited by admin on Mon Mar 31 21:35:56 GMT 2025
|
PRIMARY | |||
|
100000085719
Created by
admin on Mon Mar 31 21:35:56 GMT 2025 , Edited by admin on Mon Mar 31 21:35:56 GMT 2025
|
PRIMARY | |||
|
S1N0RH6385
Created by
admin on Mon Mar 31 21:35:56 GMT 2025 , Edited by admin on Mon Mar 31 21:35:56 GMT 2025
|
PRIMARY | |||
|
76965442
Created by
admin on Mon Mar 31 21:35:56 GMT 2025 , Edited by admin on Mon Mar 31 21:35:56 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
